FRM
SCMP

Fox Run Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Fox Run Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,800
Closed -$151K – 1005
2017
Q3 		$151K Buy
+12,800
New +$144K 0.04% 631

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Fox Run Management's SCMP Position: Q4 2017 in Review

Fox Run Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 12,800 shares — an estimated $151K sold.

Fox Run Management first reported a position in SCMP in Q3 2017 and held it in 1 quarter. The position peaked at $151K in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Fox Run Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Fox Run Management sold 12,800 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $151K.
  • Fox Run Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Fox Run Management's Sucampo Pharmaceuticals, Inc. position peaked at $151K in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Fox Run Management's 13F filing for Q4 2017, filed 18 Jan 2018.